TABLE 1.
Background of the patients for reliability and validity assessment.
| Number of patients | 38 |
|---|---|
| Basic demographics | |
| Age, years | 65 ± 11 |
| Female, n (%) | 36 (95%) |
| Disease duration, years | 9 ± 7 |
| Body mass index | 20 ± 3 |
| Autoantibodies | |
| Anti‐topoisomerase I antibody, n (%) | 10 (26%) |
| Anti‐centromere antibody, n (%) | 17 (45%) |
| Anti‐RNA polymerase III antibody, n (%) | 6 (16%) |
| Anti‐U1 ribonucleoprotein antibody, n (%) | 2 (5%) |
| Type of systemic sclerosis | |
| Limited cutaneous systemic sclerosis, n (%) | 28 (74%) |
| Diffuse cutaneous systemic sclerosis, n (%) | 8 (21%) |
| Overlap with SLE, n (%) | 2 (5%) |
| Overlap with PM/DM, n (%) | 0 (0%) |
| Skin manifestations | |
| Diffuse skin sclerosis, n (%) | 10 (26%) |
| Modified Rodnan total skin thickness score | 13 ± 9 |
| Puffy fingers, n (%) | 30 (79%) |
| Telangiectasia, n (%) | 20 (53%) |
| Calcinosis, n (%) | 5 (13%) |
| Peripheral angiopathy | |
| Normal, n (%) | 4 (11%) |
| Raynaud's phenomenon, n (%) | 16 (42%) |
| Pitting scars, n (%) | 11 (29%) |
| Digital ulcers, n (%) | 6 (16%) |
| Gangrenes, n (%) | 1 (3%) |
| N of ulcered fingers, n (%) | 3 ± 4 |
| Organ involvements | |
| Interstitial lung disease, n (%) | 16 (42%) |
| Pulmonary hypertension, n (%) | 4 (11%) |
| Scleroderma renal crisis, n (%) | 1 (3%) |
| Medications | |
| PPI, n (%) | 34 (89%) |
| Calcium channel blockers, n (%) | 7 (18%) |
| Corticosteroids, n (%) | 13 (34%) |
| Endothelin receptor antagonists, n (%) | 18 (47%) |
| Objective clinical outcome measures | |
| %FVC | 97 ± 19 |
| %DLco | 89 ± 18 |
| KL‐6 | 245 ± 75 |
| SP‐D | 72 ± 36 |
| Serum albumin, g/dL | 4.4 ± 1.0 |
| Serum TG, mg/dL | 134 ± 55 |
| Patient‐reported outcome measures | |
| F‐scale | |
| Reflux score | 7 ± 6 |
| Dyspeptic score | 6 ± 5 |
| Total score | 13 ± 11 |
| SF‐36 | |
| PF | 77 ± 22 |
| RP | 71 ± 28 |
| BP | 59 ± 24 |
| GH | 46 ± 15 |
| VT | 55 ± 20 |
| SF | 77 ± 27 |
| RE | 79 ± 26 |
| MH | 70 ± 18 |
| Physical Component Summary | 42 ± 13 |
| Mental Component Summary | 50 ± 8 |
| EQ‐5D | |
| Mobility | 0.39 ± 0.72 |
| Self‐care | 0.21 ± 0.47 |
| Usual activities | 0.66 ± 0.88 |
| Pan/discomfort | 0.87 ± 0.91 |
| Anxiety/depression | 0.42 ± 0.76 |
| VAS | 66 ± 18 |
Abbreviations: BP, bodily pain; DLco, Diffusing Capacity of the Lungs for Carbon Monoxide; DM, Dermatomyositis; EQ‐5D stands for EuroQol 5 dimensions; FVC, Forced Vital Capacity; GH, general health; KL‐6, Krebs von den Lungen‐6; MCS, mental component summary; MH, mental health; PCS, physical component summary; PF, physical functioning; PM, Polymyositis; PPI, Proton Pump; Inhibitor; RE, role emotional; RP, role physical; SP‐D, Surfactant Protein D; SF, social functioning; SF‐36, Medical Outcomes Short Form‐36; SLE, Systemic Lupus Erythematosus; TG, Triglycerides; VAS stands for "visual analogue scale; VT, vitality.
Note: Unless noted otherwise, values are means ± SD.